- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07416045
A Multi-dimensional Evaluation of the Effects of Linear Accelerator X-ray Irradiation on Red Blood Cells
February 10, 2026 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
A Multi-dimensional Evaluation of the Effects of Linear Accelerator X-ray Irradiation on the Morphology, Mechanical Properties and Functions of Red Blood Cells
This study aims to investigate the effects of linear accelerator X-ray irradiation on the structure, mechanics and functional characteristics of red blood cells recovered from patients with malignant tumors during surgery.
A red blood cell damage evaluation system based on multiple-dimensional indicators is established.
Through atomic force microscopy, microfluidic chips and biochemical detection methods, the changes in red blood cell membrane structure, deformability and oxygen-carrying capacity under different irradiation doses are systematically evaluated.
The dose-effect relationship between irradiation dose and red blood cell damage degree is clarified, providing experimental evidence for the safe dose of irradiation processing of autologous blood during surgery.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This study aims to address the current lack of systematic evaluation methods for the survival status and damage characteristics of red blood cells after irradiation treatment.
It is difficult to accurately assess the long-term functional activity of irradiated red blood cells in the body.
By combining techniques such as microtubule suction, microfluidic technology, microscopy, and cross-scale numerical simulation, this study will comprehensively evaluate the dynamic changes in the geometric shape, mechanics, and flow characteristics of red blood cells under X-ray irradiation from a linear accelerator from multiple dimensions.
It will also explore the cross-scale mechanical mechanisms of the ultrastructure, deformation, and flow characteristics changes of the red blood cell membrane caused by irradiation, providing further preclinical evidence for the transformation application of linear accelerators in the recovery of autologous blood for tumor surgery.
Study Type
Observational
Enrollment (Estimated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fengjiang Zhang
- Phone Number: +8613858007629
- Email: zrzfj@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital, School of Medicine, Zhejiang University,anesthesiology department,
-
Contact:
- Fengjiang ZHANG
- Phone Number: +8613858007629
- Email: zrzfj@zju.eud.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients aged 18 to 65 years old who are scheduled to undergo elective surgery for malignant tumors
Description
Inclusion Criteria:
- Patients scheduled for elective surgery for malignant tumors
- Age: 18 - 65 years old
- It is estimated that the surgical bleeding will be greater than or equal to 500 milliliters.
Exclusion Criteria:
- Disorders of red blood cell production (such as aplastic anemia, megaloblastic anemia, iron deficiency anemia, leukemia, myelofibrosis, etc.)
- Diseases caused by increased destruction of red blood cells (abnormalities in red blood cell membranes such as hereditary spherocytosis and paroxysmal nocturnal hemoglobinuria; abnormalities in hemoglobin such as thalassemia; abnormalities in red blood cell-related enzymes such as glucose-6-phosphate dehydrogenase deficiency, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Red blood cell biochemical indicators
Time Frame: 1day
|
The biochemical changes of the treated red blood cells were detected through methods such as blood gas analyzer and related quantitative ELISA kits.
|
1day
|
|
Mechanical characteristics of red blood cells
Time Frame: 3 day
|
The mechanical property changes of red blood cells after treatment were detected by techniques such as microtubule suction and microfluidics
|
3 day
|
|
Morphological characteristics of red blood cells
Time Frame: 1day
|
Using scanning electron microscope (SEM) and transmission electron microscope (TEM), observe the changes in the surface structure and ultrastructure of the red blood cell membrane.
Also, study the morphological alterations of red blood cells.
|
1day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Circulating tumor cell clearance indicator
Time Frame: 1 day
|
Adopt the method of immunofluorescence staining for testing, qualitative or half quantitative analysis by fluorescence microscope, in the evaluation of circulating tumor cells in the blood after processing residues.
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 28, 2026
Primary Completion (Estimated)
February 26, 2027
Study Completion (Estimated)
February 26, 2027
Study Registration Dates
First Submitted
February 10, 2026
First Submitted That Met QC Criteria
February 10, 2026
First Posted (Actual)
February 17, 2026
Study Record Updates
Last Update Posted (Actual)
February 17, 2026
Last Update Submitted That Met QC Criteria
February 10, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 2024-0164
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erythrocyte Destruction
-
Anthea Hospital BariWithdrawnInflammatory Response | Hemolysis | Cardiovascular Disorder | Red Blood Cell Disorder | Erythrocyte DestructionItaly
-
Dr R Viswa ChandraRecruitingGingival DestructionIndia
-
I.M. Sechenov First Moscow State Medical UniversityCompletedCartilage DestructionRussian Federation
-
Duke UniversityZimmer BiometTerminated
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiac Surgery | Erythrocyte TransfusionUnited States
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiac Surgery | Erythrocyte TransfusionUnited States
-
Gorm GreisenFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoCompletedErythrocyte Transfusion | Cerebral HaemodynamicsItaly
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Centre Hospitalier Universitaire de BesanconCentre Hospitalier Universitaire Dijon; Etablissement Français du SangCompletedErythrocyte Transfusion for All ConditionsFrance
-
Samsung Medical CenterCompletedPercutaneous Coronary Intervention | Erythrocyte Transfusion | RevascularizationKorea, Republic of